Aqara Launches Amazon Brand Stores in Italy and Spain
Aqara, a leading provider of smart home products, announced the debut of its brand stores on Amazon.it and Amazon.es. Since the launch of Aqara’s first European brand store on Amazon UK in July 2021, the smart home manufacturer has expanded its Amazon presence to France, Germany, Italy and Spain, making the comprehensive portfolio of Aqara products easily accessible for smart home users across Europe.
Aqara has been selling in Italy and Spain on the Apple Online Store and via local retailers, and the brand has become increasingly popular among the local users for the build quality, the accessible prices and the wide compatibility with major ecosystems including HomeKit, Alexa, and Google Home. The launch of its Amazon brand stores will bring more Aqara products to the local markets, ranging from smart home hubs, smart sensors, security cameras, wired and wireless switches, to smart shade controllers.
The product lineup of the Aqara brand stores on Amazon.it and Amazon.es include:
Camera Hub G3 - Aqara’s flagship pan-and-tilt home security camera with AI-enabled facial and gesture recognition, built-in Zigbee hub function, as well as wide third-party ecosystem support (HomeKit, Alexa, Google Home);
Camera Hub G2H Pro - An indoor HomeKit Secure Video camera for home security, with the Zigbee hub function to enhance home security and smart home automations;
Hub M2 - The versatile and future-proof smart home hub that connects all Aqara devices and allows seamless integration across Aqara sensors and home automation devices;
Hub M1S - The wireless control center of Aqara accessories enabling home automation, local alarm, and remote control of smart devices, while it can also be used as a night light, siren, or doorbell;
Hub E1 - Aqara’s smallest smart home hub with a UBS-A port and adjustable shaft, allowing it to be flexibly placed and charged by USB devices such as PCs, power strips and outlets;
Door & Window Sensor - It detects when a window or a door is open in real time, and enables push notifications or/and local siren when the door/window opens unexpectedly;
Temperature & Humidity Sensor - It monitors temperature, humidity and atmospheric pressure in real time, and can connect with other Aqara devices for home automations and scenes;
Motion Sensor - It detects human movements with passive infrared and can work with other Aqara products to set home automations and scenes;
Motion Sensor P1 - An enhanced version of the iconic Motion Sensor, with a prolonged battery life of up to 5 years, and the configurable detection timeout as well as sensitivity levels;
Water Leak Sensor - It detects flood, and enables push notifications or/and local alarm activation to protect the property;
Vibration Sensor - It detects vibration, tilt and drop, alerts users when unexpected movement is detected, and can be used for home automations and scenes;
TVOC Air Quality Monitor - It detects the level of total volatile organic compounds (TVOC) in the air, as well as temperature and humidity, and can be used to enable push notifications, local siren, and home automations;
Smart Wall Switch H1 EU* - Aqara’s first wall switch designed for Europe, supporting both round European wall boxes and 86 mm square wall boxes and available in both With Neutral and No Neutral versions;
Smart Plug EU - It automates ordinary home appliances, and enables the remote control and timer switch of lights, fans, and other appliances.
Roller Shade Driver E1 - A retrofit roller shade controller to automate regular beaded-cord roller blinds, allowing users to set the shades by mobile control, voice command, preset schedule or via home automations;
Wireless Switch H1 - A remote switch with 7 configurable actions to control smart home devices or home scenes;
Wireless Mini Switch - A versatile and compact switch with 3 configurable actions to control smart home devices or home scenes;
Cube - A versatile controlling cube that recognizes 6 gestures (push, shake, rotate, tap twice, flip 90°, and flip 180°) for smart home control.
To celebrate the launch, Aqara now offers a limited-time offer of 5% extra discount for purchases on its Amazon.it store and Amazon.es store with the promo code AMAZONITES**. The offering is valid through May 19, 2022.
* Smart Wall Switch H1 EU is not available on Amazon.it.
** Promo code can be combined with coupons. Offer excludes the Hub M1S, the Camera Hub G3 and the Door & Window Sensor on Amazon.it, and excludes the Camera Hub G3 on Amazon.es.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005102/en/
Contact information
For Media Inquiry:
Michell Li
Mobile: +86 18501199430
Email: media@aqara.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom